InforMax Announces GenoMax(TM) License Agreement With Abgenix, Inc.
BETHESDA, Md., May 10 /PRNewswire/ -- InforMax, Inc. (Nasdaq: INMX), a leading global provider of bioinformatics software solutions, today announced that in the first quarter ending March 31, 2001 it signed a license agreement with Abgenix Inc. for GenoMax(TM) enterprise software.
(Photo: newscom.com )
Rapidly becoming an industry standard, GenoMax(TM) is an enterprise bioinformatics system that supports High-Throughput Research(TM) (HTR), a process for minimizing the time and cost of discovery while finding valuable targets for pharmaceutical, therapeutic, and diagnostic development. GenoMax(TM) is a modular family of analysis programs, each designed specifically to work with one or more types of genomic and proteomic data, including sequence information, gene expression data, protein structure, and protein-protein interactions.
Keith Joho, Ph.D., Director of Bioinformatics for Abgenix, said, "The GenoMax bioinformatics system will help us to organize and manage the genomics data for our antibody-based therapeutics. We expect GenoMax to help expedite our analysis of targets and antibodies in our large-scale product discovery efforts."
"We are pleased to be part of Abgenix's research efforts," said Alex Titomirov, Ph.D., InforMax chief executive officer and chairman. "Our GenoMax enterprise platform has been sold to 32 pharmaceutical, biotechnology, and academic customers and is designed to help customers like Abgenix dramatically enhance their discovery research programs."
About Abgenix
Abgenix is a biopharmaceutical company focused on the development and commercialization of fully human monoclonal antibody therapies for a variety of diseases. The company's antibody technology platform, which includes XenoMouse(TM) technology, enables the rapid generation and selection of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix leverages its leadership position in human antibody technology by building a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products. For more information on Abgenix, visit the company's website at abgenix.com .
About InforMax
InforMax is a leading global developer of bioinformatics software for High-Throughput Research(TM). InforMax products are used by 1,870 research organizations and more than 25,000 individual scientists worldwide (as of March 31, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among the Company's customers are 23 of the top 25 pharmaceutical companies. InforMax was founded in 1990 by Alex Titomirov, Ph.D. The Company's mission is to support the scientific community in drug discovery and to better understand the causes of disease. Our High-Throughput Research(TM) and comprehensive suite of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover effective treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI(R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax (TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the Company's Web site at informaxinc.com . |
